AbbVie Inc. (ABBV)

US — Healthcare Sector
Peers: MRK  PFE  LLY  BMY  JNJ  AMGN  GILD 

Automate Your Wheel Strategy on ABBV

With Tiblio's Option Bot, you can configure your own wheel strategy including ABBV - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol ABBV
  • Rev/Share 32.9165
  • Book/Share 0.8251
  • PB 257.3019
  • Debt/Equity 49.2176
  • CurrentRatio 0.7602
  • ROIC 0.1413

 

  • MktCap 364247006400.0
  • FreeCF/Share 8.6823
  • PFCF 23.6755
  • PE 96.9405
  • Debt/Assets 0.5133
  • DivYield 0.0314
  • ROE 0.8588

 

  • Rating C
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 5
  • P/B Score 1
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Resumed ABBV Piper Sandler -- Overweight -- $231 Aug. 12, 2025
Upgrade ABBV Daiwa Securities Neutral Outperform -- $214 Aug. 7, 2025
Downgrade ABBV Citigroup Buy Neutral -- $205 May 14, 2025
Initiation ABBV Cantor Fitzgerald -- Overweight -- $210 April 22, 2025
Resumed ABBV BofA Securities -- Neutral -- $191 Dec. 10, 2024
Downgrade ABBV Daiwa Securities Outperform Neutral -- $180 Dec. 5, 2024
Initiation ABBV Bernstein -- Market Perform -- $203 Oct. 17, 2024

News

AbbVie Rises 11.5% in a Month: Buy, Hold or Sell the Stock?
ABBV
Published: August 20, 2025 by: Zacks Investment Research
Sentiment: Positive

AbbVie jumps 11.5% in a month on strong Q2 results, raised guidance and momentum from Skyrizi, Rinvoq and neuroscience growth.

Read More
image for news AbbVie Rises 11.5% in a Month: Buy, Hold or Sell the Stock?
Here is What to Know Beyond Why AbbVie Inc. (ABBV) is a Trending Stock
ABBV
Published: August 18, 2025 by: Zacks Investment Research
Sentiment: Positive

AbbVie (ABBV) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Read More
image for news Here is What to Know Beyond Why AbbVie Inc. (ABBV) is a Trending Stock
My 3 Favorite Stocks to Buy Right Now
ABBV, COST, UBER
Published: August 10, 2025 by: The Motley Fool
Sentiment: Positive

Short-term market fluctuations can be stressful, there's no doubt about that. The good news is, long-term investors are in a better position to weather these storms.

Read More
image for news My 3 Favorite Stocks to Buy Right Now
Jim Cramer Says To Buy These 3 Dividend Stocks ASAP
ABBV, ENB, O
Published: August 05, 2025 by: 24/7 Wall Street
Sentiment: Positive

Jim Cramer likes these dividend stocks for 2025. All three dividend stocks are solid financially and pay good yields.

Read More
image for news Jim Cramer Says To Buy These 3 Dividend Stocks ASAP
AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know
ABBV
Published: August 05, 2025 by: Zacks Investment Research
Sentiment: Positive

Zacks.com users have recently been watching AbbVie (ABBV) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Read More
image for news AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
ABBV, PODD
Published: August 05, 2025 by: Zacks Investment Research
Sentiment: Positive

Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.

Read More
image for news Why Investors Need to Take Advantage of These 2 Medical Stocks Now
The Big 3: ABBV, ETSY, VRT
ABBV, ETSY
Published: August 04, 2025 by: Schwab Network
Sentiment: Positive

Mike Shorr (@ProsperTradingAcademy) walks through a pair of stocks he sees set up for a swing breakout: AbbVie (ABBV) and Etsy Inc. (ETSY). For both, he demonstrates an example options trade using a call spread.

Read More
image for news The Big 3: ABBV, ETSY, VRT
How Did Skyrizi and Rinvoq Sales Contribute to AbbVie's Q2 Results?
ABBV
Published: August 04, 2025 by: Zacks Investment Research
Sentiment: Positive

AbbVie's Q2 results show Skyrizi and Rinvoq powering growth, offsetting Humira declines and lifting 2025 sales outlook.

Read More
image for news How Did Skyrizi and Rinvoq Sales Contribute to AbbVie's Q2 Results?
AbbVie Inc. (ABBV) Q2 2025 Earnings Call Transcript
ABBV
Published: July 31, 2025 by: Seeking Alpha
Sentiment: Neutral

AbbVie Inc. (NYSE:ABBV ) Q2 2025 Earnings Conference Call July 31, 2025 9:00 AM ET Company Participants Elizabeth Shea - Senior Vice President of Investor Relations Jeffrey Ryan Stewart - Executive VP & Chief Commercial Officer Robert A. Michael - CEO & Chairman of the Board Roopal Thakkar - Executive VP of Research and Development & Chief Scientific Officer Scott T.

Read More
image for news AbbVie Inc. (ABBV) Q2 2025 Earnings Call Transcript
AbbVie Stock Eyes Breakout as Pipeline and Profits Grow
ABBV
Published: July 31, 2025 by: MarketBeat
Sentiment: Positive

AbbVie Inc. NYSE: ABBV stock is up nearly 2% in midday trading after delivering a beat-and-raise in its second-quarter 2025 earnings report. The biopharmaceutical giant reported global net revenue of $15.42 billion, beating expectations for $14.93 billion.

Read More
image for news AbbVie Stock Eyes Breakout as Pipeline and Profits Grow
AbbVie Beats on Q2 Earnings & Sales, Stock Up on Raised '25 EPS View
ABBV
Published: July 31, 2025 by: Zacks Investment Research
Sentiment: Positive

ABBV tops Q2 forecasts and lifts 2025 EPS outlook as Rinvoq and Skyrizi drive growth amid Humira's decline.

Read More
image for news AbbVie Beats on Q2 Earnings & Sales, Stock Up on Raised '25 EPS View
PCE Comes in Warmer Than Expected
AAPL, ABBV, ADP, AMZN, BMY, CVS, IP, MA, MSFT, PMI, ROKU, SIRI
Published: July 31, 2025 by: Zacks Investment Research
Sentiment: Neutral

PCE Comes in Warmer Than Expected.

Read More
image for news PCE Comes in Warmer Than Expected
Economy Heating Up on PCE for June
AAPL, ABBV, ADP, AMZN, BMY, CVS, IP, MA, MSFT, PMI, ROKU, SIRI
Published: July 31, 2025 by: Zacks Investment Research
Sentiment: Neutral

Pre-market and bond yield numbers appear to be in reaction to this morning's economic posts.

Read More
image for news Economy Heating Up on PCE for June
AbbVie (ABBV) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
ABBV
Published: July 31, 2025 by: Zacks Investment Research
Sentiment: Neutral

While the top- and bottom-line numbers for AbbVie (ABBV) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Read More
image for news AbbVie (ABBV) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
AbbVie (ABBV) Tops Q2 Earnings and Revenue Estimates
ABBV
Published: July 31, 2025 by: Zacks Investment Research
Sentiment: Positive

AbbVie (ABBV) came out with quarterly earnings of $2.97 per share, beating the Zacks Consensus Estimate of $2.89 per share. This compares to earnings of $2.65 per share a year ago.

Read More
image for news AbbVie (ABBV) Tops Q2 Earnings and Revenue Estimates
Sell AbbVie Stock Ahead of Its Upcoming Earnings?
ABBV
Published: July 30, 2025 by: Forbes
Sentiment: Negative

AbbVie (NYSE:ABBV) is scheduled to release its earnings report on Thursday, July 31, 2025. For event-driven traders, understanding historical stock performance around earnings announcements can be a valuable tool.

Read More
image for news Sell AbbVie Stock Ahead of Its Upcoming Earnings?
AbbVie Announces Positive Topline Results from Phase 3 UP-AA Trial Evaluating Upadacitinib (RINVOQ®) for Alopecia Areata
ABBV
Published: July 30, 2025 by: PRNewsWire
Sentiment: Neutral

In Study 2 of the pivotal Phase 3 UP-AA clinical program, upadacitinib (RINVOQ®) achieved the primary endpoint, demonstrating that 44.6% and 54.3% of patients with severe alopecia areata treated with upadacitinib 15 mg and 30 mg, respectively, reached 80% or more scalp hair coverage at week 24 as defined by the severity of alopecia tool (SALT) score ≤ 201 Key secondary endpoints, including improvements in eyebrows and eyelashes, as well as the percentage of subjects with 90% or more scalp coverage (SALT ≤ 10) and complete scalp hair coverage (SALT=0) at week 24, were also met1 The safety profile in …

Read More
image for news AbbVie Announces Positive Topline Results from Phase 3 UP-AA Trial Evaluating Upadacitinib (RINVOQ®) for Alopecia Areata
4 Safe High-Yielding Dividend Aristocrats Are Our Top Picks in a Dangerous Market
ABBV, KVUE, PEP, XOM
Published: July 30, 2025 by: 24/7 Wall Street
Sentiment: Positive

Investors seeking defensive companies that pay substantial dividends are drawn to the Dividend Aristocrats, and with good reason.

Read More
image for news 4 Safe High-Yielding Dividend Aristocrats Are Our Top Picks in a Dangerous Market
Top 10 Income Funds From Eaton Vance
AAPL, ABBV
Published: July 29, 2025 by: Seeking Alpha
Sentiment: Positive

Eaton Vance's top taxable closed-end funds offer reliable monthly income, strong long-term returns, and are managed by highly skilled teams with proven track records. I prioritize funds trading at a discount to NAV with distribution yields near or above 8%, focusing on both income and capital appreciation potential. For total return, EOS and EOI are top picks; for dividend income, EVT (domestic) and ETG (global) provide diversification and attractive yields.

Read More
image for news Top 10 Income Funds From Eaton Vance
Pre-Q2 Earnings: Is AbbVie Stock a Portfolio Must-Have?
ABBV
Published: July 28, 2025 by: Zacks Investment Research
Sentiment: Positive

ABBV's Q2 results are likely to hinge on Skyrizi and Rinvoq growth as Humira declines, with 2025 set for a strong revenue rebound.

Read More
image for news Pre-Q2 Earnings: Is AbbVie Stock a Portfolio Must-Have?
Will These 5 Pharma/Biotech Bigwigs Surpass Q2 Earnings Forecasts?
ABBV, AZN, BMY, MRK, MRNA
Published: July 28, 2025 by: Zacks Investment Research
Sentiment: Positive

Let's look at five biotech and drug companies, MRK, AZN, BMY, ABBV and MRNA, slated to release their second-quarter 2025 results this week.

Read More
image for news Will These 5 Pharma/Biotech Bigwigs Surpass Q2 Earnings Forecasts?
AbbVie (ABBV) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
ABBV
Published: July 24, 2025 by: Zacks Investment Research
Sentiment: Neutral

AbbVie (ABBV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Read More
image for news AbbVie (ABBV) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Final Trades: Abbvie, Uber, Western Union and Live Nation
ABBV, LYV, UBER, WU
Published: July 23, 2025 by: CNBC Television
Sentiment: Neutral

(OPTIMIZED VIDEO SPECIFIC DESCRIPTION)

Read More
image for news Final Trades: Abbvie, Uber, Western Union and Live Nation
4 Reasons To Buy AbbVie
ABBV
Published: July 22, 2025 by: Seeking Alpha
Sentiment: Neutral

I maintain my Buy rating on AbbVie, emphasizing its medium-to-long-term potential despite recent outlook downgrades and tariff risks. Recent guidance cuts are minor and don't meaningfully undermine the investment case; with earnings growth expected in Q2 2025. The company's dividends add to its attractiveness at an uncertain time, adding to robust price returns over time.

Read More
image for news 4 Reasons To Buy AbbVie
How Will AbbVie's Neuroscience Franchise Perform in Q2 Earnings?
ABBV
Published: July 22, 2025 by: Zacks Investment Research
Sentiment: Positive

ABBV's neuroscience sales are projected to jump 15% in Q2, driven by Botox Therapeutic, Vraylar and oral migraine drug gains.

Read More
image for news How Will AbbVie's Neuroscience Franchise Perform in Q2 Earnings?
Best Dividend Kings: July 2025
ABBV, ABM, ABT, ADM, ADP, AWR, BDX, BKH, CBSH, CINF, CL, CWT, DOV, ED, EMR, FMCB, FRT, FUL, GPC, GRC, GWW, HRL, HTO, ITW, JNJ
Published: July 22, 2025 by: Seeking Alpha
Sentiment: Positive

14 Dividend Kings continue to outperform the S&P 500 in 2025. Dividend growth remains healthy, with one recent increase and a collective 2025 growth rate of 5.23%. Seventeen Dividend Kings currently appear undervalued with strong long-term return potential, using Dividend Yield Theory for valuation.

Read More
image for news Best Dividend Kings: July 2025
July's 5 Dividend Growth Stocks With Yields Up To 7.96%
ABBV, APAM, BLK, BMY, EBF, MRK, NWE, PFE, RLJ, STT, TROW, UPS, WU
Published: July 18, 2025 by: Seeking Alpha
Sentiment: Positive

Dividend growth stocks can offer a stable way to passively grow one's income, creating long-term compounding wealth over the long run. Today, we are looking at a screening process that focuses on higher yields but ranks higher on dividend safety and consistency for growth. From the hundreds that end up listed, we take a look at some of those that rank on the higher yield end for an initial look.

Read More
image for news July's 5 Dividend Growth Stocks With Yields Up To 7.96%
AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know
ABBV
Published: July 18, 2025 by: Zacks Investment Research
Sentiment: Positive

AbbVie (ABBV) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Read More
image for news AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know
AbbVie (ABBV) Surpasses Market Returns: Some Facts Worth Knowing
ABBV
Published: July 16, 2025 by: Zacks Investment Research
Sentiment: Positive

The latest trading day saw AbbVie (ABBV) settling at $190.58, representing a +2.25% change from its previous close.

Read More
image for news AbbVie (ABBV) Surpasses Market Returns: Some Facts Worth Knowing
How Will AbbVie's Oncology Drugs Aid Upcoming Q2 Results?
ABBV
Published: July 16, 2025 by: Zacks Investment Research
Sentiment: Negative

ABBV's oncology sales might have dipped in Q2 as gains from newer drugs face pressure from Imbruvica's ongoing decline.

Read More
image for news How Will AbbVie's Oncology Drugs Aid Upcoming Q2 Results?

About AbbVie Inc. (ABBV)

  • IPO Date 2013-01-02
  • Website https://www.abbvie.com
  • Industry Drug Manufacturers - General
  • CEO Robert A. Michael CPA
  • Employees 55000

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.